Lupin receives approval from USFDA for Brexpiprazole Tablets
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
Brexpiprazole Tablets, 0.25 mg, 0.5 mg, 1 mg, 2 mg, 3 mg, and 4 mg, (RLD Rexulti) had estimated annual sales of US $1,575 million in the US (IQVIA MAT December 2022)
ZYIL1 is a novel oral small molecule NLRP3 inhibitor which has demonstrated CSF penetration in non-human primates
Subgroup analysis by HER2 expression from phase 1/2 trial of patients with HER3 expressing metastatic breast cancer highlighted in a second Presidential Session
The antiviral is efficacious in non-human primates, and is safe and well-tolerated in humans
KRIVIDA TRIVUS detects the specific virus causing a respiratory infection.
Spain’s renowned centre of excellence recognises importance of verifying radiosurgery plans ahead of patient treatment
Dr. Hubbard brings more than 35 years of experience in the biopharmaceutical and pharma-tech services industries and CROs.
For the first-line treatment of patients with unresectable advanced or metastatic malignant pleural mesothelioma
IIT Kanpur pioneers ground-breaking gene therapy technology for Hereditary Eye Diseases
Subscribe To Our Newsletter & Stay Updated